US EditionPublished • loading... • Updated
Samsung Bioepis Thrives in U.S. and Europe Ahead of Independence
Summary by businesskorea.co.kr
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Samsung Bioepis Thrives in U.S. and Europe Ahead of Independence
Samsung Bioepis headquarters in Songdo, Incheon (Photo courtesy of Samsung Bioepis) Samsung Bioepis, preparing for independent management under Samsung Epis Holdings through a spin-off from Samsung Biologics, has shown strong performance in the third quarter of this year. The success is largely attributed to the “private label (PL)” biosimilar of the autoimmune treatment “Stelara,” which began supply to U.S. pharmacy benefit managers (PBMs) in t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
